Literature DB >> 9272205

Pathogenetic implication of interleukin-2 expressed in preeclamptic decidual tissues: a possible mechanism of deranged vasculature of the placenta associated with preeclampsia.

Y Hamai1, T Fujii, T Yamashita, S Kozuma, T Okai, Y Taketani.   

Abstract

PROBLEM: The purpose of this study is to clarify whether IL-2 expressed in the decidua in preeclampsia affects the angiogenesis of the placenta. METHOD OF STUDY: We investigated the angiogenic substances released from human trophoblasts obtained from early pregnancy that had been pretreated with either IL-2, non-activated lymphocytes from peripheral blood mononuclear cells (PBMCs), decidual lymphocytes, or these lymphocytes activated by lymphokine (LAK cells). Angiogenic activity was determined by evaluating the ability of growth-promotion of cultured human microvascular endothelial cells (HMvECs) using MTT assay.
RESULTS: Trophoblasts pretreated with IL-2 or non-activated lymphocytes, irrespective of their origin, released angiogenic factor similar to those without pretreatment. However, trophoblasts pretreated with LAK cells released less angiogenic factor compared with those without pretreatment.
CONCLUSIONS: Interleukin-2 (IL-2) expressed in preeclamptic decidua might reduce the angiogenic substances arising from trophoblasts by inducing LAK-cells from decidual lymphocytes, which might be relevant to deranged vasculature of the placenta, a characteristic histology in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272205     DOI: 10.1111/j.1600-0897.1997.tb00280.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  2 in total

1.  Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.

Authors:  J A Jordan; D Huff; J A DeLoia
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Serum levels of neopterin and interleukin-2 receptor in women with severe preeclampsia.

Authors:  Ilknur Kaleli; Babur Kaleli; Melek Demir; Basak Yildirim; Nural Cevahir; Suleyman Demir
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.